EYEN

Eyenovia, Inc. [EYEN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

EYEN Stock Summary

Top 10 Correlated ETFs

EYEN


Top 10 Correlated Stocks

EYEN


In the News

08:52 29 Mar 2024 EYEN

Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript

Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript

06:21 29 Mar 2024 EYEN

Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates

Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.

07:00 29 Mar 2024 EYEN

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

06:08 29 Mar 2024 EYEN

US FDA approves Eyenovia's eye drug, Formosa Pharma says

The U.S. Food and Drug Administration approved Eyenovia's eye drops to reduce inflammation and pain in patients who have undergone eye surgery, Formosa Pharmaceuticals said on Monday.

02:45 29 Mar 2024 EYEN

Eyenovia: Racing Toward The Finish Line

Eyenovia has received FDA approval for its Optejet system, which revolutionizes how eye medications are dosed, resolving limitations and adverse events caused by traditional eye droppers. The company's manufacturing facilities, including two in the USA and one in Mexico, have received FDA certification, ensuring the safety and quality of their products. Eyenovia is preparing for the official launch of its first FDA-approved product, MydCombi, and has upcoming events, including financial results and an FDA decision for another drug.

08:17 29 Mar 2024 EYEN

7 Promising Penny Stocks With the Potential to Defy Expectations

You know you want it. High-potential penny stocks that is.

09:34 29 Mar 2024 EYEN

Eyenovia, Inc. (EYEN) Q3 2023 Earnings Call Transcript

Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Glenn Garmont - LifeSci Partners, IR Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Bren Kern - Chief Operating Officer Conference Call Participants John Boyle - William Blair Raymond Wu - Ladenburg Thalmann Len Yaffe - Stoc*Doc Partners Operator Good day, ladies and gentlemen. And welcome to Eyenovia's Third Quarter of 2023 Earnings Conference Call.

08:16 29 Mar 2024 EYEN

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

08:00 29 Mar 2024 EYEN

Eyenovia to Report Third Quarter 2023 Results on Monday, November 13

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

11:32 29 Mar 2024 EYEN

7 Penny Stocks To Buy Now According To Analysts, Targets Up To 751%

The penny stock market is an enticing yet volatile landscape for investors seeking big rewards. While the chance to uncover the next hidden gem before it rockets higher is enticing.

EYEN Financial details

Company Rating
Neutral
Market Cap
54.02M
Income
-28M
Revenue
3.79K
Book val./share
0.2
Cash/share
0.33
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-3.04
Forward P/E
-1.11
PEG
1.92
P/S
72554.87
P/B
5.01
P/C
2.99
P/FCF
-3.21
Quick Ratio
3.3
Current Ratio
4.05
Debt / Equity
1.65
LT Debt / Equity
1
-
-
EPS (TTM)
-0.69
EPS next Y
-0.89
EPS next Q
-0.23
EPS this Y
-19.51%
EPS next Y
29.35%
EPS next 5Y
-199.28%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
116.11%
EPS Q/Q
-
-
-
-
-
SMA20
-40.51%
SMA50
-34.83%
SMA100
-7.2%
Inst Own
20.89%
Inst Trans
1.23%
ROA
-74%
ROE
-175%
ROC
-0.82%
Gross Margin
-
Oper. Margin
-1945924%
Profit Margin
-2167766%
Payout
-
Shs Outstand
47.39M
Shs Float
38.6M
-
-
-
-
Target Price
-
52W Range
1.05-5.85
52W High
-80.28%
52W Low
-1.4%
RSI
28.75
Rel Volume
0.93
Avg Volume
834.11K
Volume
779.26K
Perf Week
-16.44%
Perf Month
-44.61%
Perf Quarter
-37.99%
Perf Half Y
-39.88%
-
-
-
-
Beta
1.719
-
-
Volatility
0.09%, 0.38%
Prev Close
-0.04%
Price
0.986
Change
-2.38%

EYEN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.090.5300
Net income per share
-1.46-0.94-0.49-0.82-0.66
Operating cash flow per share
-1.32-0.3-0.79-0.75-0.58
Free cash flow per share
-1.33-0.32-0.85-0.77-0.68
Cash per share
0.991.350.740.680.36
Book value per share
0.820.730.780.510.22
Tangible book value per share
0.820.730.780.510.17
Share holders equity per share
0.820.730.780.510.22
Interest debt per share
00.020.290.340.42
Market cap
64.29M127.59M105.3M54.85M85.35M
Enterprise value
50.18M99.68M92.98M42.11M86.61M
P/E ratio
-3.06-6.48-8.1-1.98-3.13
Price to sales ratio
063.87.52022.54K
POCF ratio
-3.4-19.99-5.04-2.18-3.58
PFCF ratio
-3.37-19.2-4.68-2.11-3.07
P/B Ratio
5.488.345.143.189.48
PTB ratio
5.488.345.143.189.48
EV to sales
049.846.64022.87K
Enterprise value over EBITDA
-2.35-5.05-7.23-1.58-3.52
EV to operating cash flow
-2.65-15.61-4.45-1.68-3.63
EV to free cash flow
-2.63-15-4.13-1.62-3.11
Earnings yield
-0.33-0.15-0.12-0.51-0.32
Free cash flow yield
-0.3-0.05-0.21-0.47-0.33
Debt to equity
00.030.350.591.65
Debt to assets
00.010.230.330.51
Net debt to EBITDA
0.661.410.960.48-0.05
Current ratio
4.931.831.976.131.73
Interest coverage
0-1.16K-33.28-19.5-10.71
Income quality
0.890.321.630.90.87
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
03.860.7702.99K
Research and developement to revenue
06.631.0403.22K
Intangibles to total assets
00000.07
Capex to operating cash flow
0.010.040.080.030.17
Capex to revenue
0-0.13-0.120-1.05K
Capex to depreciation
-10.86-2.74-7.3-2.85-5.07
Stock based compensation to revenue
01.240.210659.6
Graham number
5.193.912.943.081.81
ROIC
-1.79-1.25-0.48-0.93-1.01
Return on tangible assets
-1.43-0.58-0.41-0.89-1.02
Graham Net
0.780.610.370.35-0.11
Working capital
11.44M15.19M10.83M23.13M6.92M
Tangible asset value
11.74M15.3M20.47M17.23M6.88M
Net current asset value
11.39M14.79M10.81M13.84M-3.33M
Invested capital
00.030.350.591.65
Average receivables
47.62K1.53M2.39M1.49M904.15K
Average payables
1.53M1.5M1.54M1.52M1.59M
Average inventory
-47.62K752.38K800K1.78M1.84M
Days sales outstanding
0541.347.06060.19K
Days payables outstanding
36.67K666.88368.221.7K813.1
Days of inventory on hand
-2.27K73004.24K50.92
Receivables turnover
00.677.7600.01
Payables turnover
0.010.550.990.220.45
Inventory turnover
-0.160.500.097.17
ROE
-1.79-1.29-0.63-1.61-3.03
Capex per share
-0.01-0.01-0.06-0.03-0.1

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.18-0.17-0.16-0.18-0.18
Operating cash flow per share
-0.16-0.19-0.12-0.15-0.14
Free cash flow per share
-0.17-0.21-0.16-0.19-0.14
Cash per share
0.680.490.460.520.33
Book value per share
0.510.420.280.390.2
Tangible book value per share
0.510.420.280.340.15
Share holders equity per share
0.510.420.280.390.2
Interest debt per share
0.330.310.440.380.34
Market cap
54.85M132.06M90.28M66.63M94.44M
Enterprise value
42.11M124.59M88.95M61.92M95.69M
P/E ratio
-2.31-5.1-3.63-2.27-2.96
Price to sales ratio
00055.62K36.48K
POCF ratio
-10.15-18.98-19.15-11.41-14.94
PFCF ratio
-9.59-16.76-15.26-8.83-14.6
P/B Ratio
3.188.358.584.2210.49
PTB ratio
3.188.358.584.2210.49
EV to sales
00051.68K36.96K
Enterprise value over EBITDA
-8.07-23.57-15.72-9.5-13.31
EV to operating cash flow
-7.79-17.9-18.87-10.6-15.14
EV to free cash flow
-7.37-15.81-15.04-8.21-14.8
Earnings yield
-0.11-0.05-0.07-0.11-0.08
Free cash flow yield
-0.1-0.06-0.07-0.11-0.07
Debt to equity
0.590.71.531.011.65
Debt to assets
0.330.380.550.460.51
Net debt to EBITDA
2.441.410.240.72-0.18
Current ratio
6.135.095.734.051.73
Interest coverage
-5.94-12.02-10.689.6-10.97
Income quality
0.881.210.760.80.79
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0002.46K1.12K
Research and developement to revenue
0002.99K1.46K
Intangibles to total assets
0000.060.07
Capex to operating cash flow
0.060.130.250.290.02
Capex to revenue
000-1.42K-56.1
Capex to depreciation
-3.97-4.67123.1-5.35-0.52
Stock based compensation to revenue
000511.66221.02
Graham number
1.431.281.011.270.88
ROIC
-0.18-0.22-0.23-0.19-0.3
Return on tangible assets
-0.19-0.22-0.21-0.22-0.3
Graham Net
0.350.20.020.06-0.1
Working capital
23.13M20.02M19.21M19.98M6.92M
Tangible asset value
17.23M15.81M10.52M13.66M6.88M
Net current asset value
13.84M11.43M4.45M7.45M-3.33M
Invested capital
0.590.71.531.011.65
Average receivables
996.61K1.08M701.34K663.35K761.11K
Average payables
1.27M1.42M1.36M1.37M1.59M
Average inventory
7.37M3.52M3.53M1.81M80.05K
Days sales outstanding
00067.44K21.71K
Days payables outstanding
1.64K640.46435.63107.13K563.29
Days of inventory on hand
4.09K1.59K1.19K3.78K35.28
Receivables turnover
00000
Payables turnover
0.050.140.2100.16
Inventory turnover
0.020.060.080.022.55
ROE
-0.34-0.41-0.59-0.47-0.89
Capex per share
-0.01-0.02-0.03-0.040

EYEN Frequently Asked Questions

What is Eyenovia, Inc. stock symbol ?

Eyenovia, Inc. is a US stock , located in New york of Ny and trading under the symbol EYEN

What is Eyenovia, Inc. stock quote today ?

Eyenovia, Inc. stock price is $0.986 today.

Is Eyenovia, Inc. stock public?

Yes, Eyenovia, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap